|drug3873||hydroxychloroquine in combination with camostat mesylate Wiki||1.00|
|D014777||Virus Diseases NIH||0.10|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
Patients with COVID-19 which are 60 years old or above or with comorbidities are at risk of deteriorating and developing severe illness. This prospective open label study will include people 60 years old or above or younger if at risk for severe disease. Individuals confirmed to have SARS-CoV-2 infection will be identified using medical records screening. They will then be offered to participate in the study and if agree will be given the informed consent. After examining inclusion and exclusion criteria they will be asked to sign the informed consent and after signing Information like immunizations, ECG results, diagnostic images and reports, written medical reports, diagnostic lab testing results (e.g. blood tests, urine tests, blood bank info), allergies and intolerances (drug and food allergies, food intolerances), prescription history, and general patient information (e.g. name, birthdate, personal health number, address, phone number) will be gathered. Those who are not eligible for the study will be informed of the reason(s) for ineligibility (generally it will be a safety exclusion and they should be aware of this). Those who are eligible will be randomized to one of three arms: hydroxychloroquine + azithromycin, hydroxychloroquine + camostat mesylate or "doing nothing" in a ratio of 2:1:2. Study drug will be dispensed by the hospital pharmacy. Follow up will continue for 8 weeks.
Description: the clinical state of the patient regarding respiratory state as defined by the NEWS scoring systemMeasure: clinical state as reflected by NEWS scoring Time: 7 days
Description: positive PCR SARS COVID 2 in the respiratory systemMeasure: positive PCR Time: 7 days
Description: prevention of hospitaliztion in the ICUMeasure: prevention of ICU Time: 14 days
Description: prevention of assisted ventilationMeasure: prevention of assisted ventilation Time: 14 days
Description: prevention of Extracorporeal Membrane Oxygenation (ECMO)Measure: prevention of ECMO Time: 14 days
Description: deathMeasure: death Time: 14 days
Description: positive PCR SARS COVID 2 in the respiratory systemMeasure: positive PCR Time: 14 days
Description: deathMeasure: death Time: 60 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports